AFP and hepatocellular carcinoma: But one thing should be clear that we introduced a novel HCC prognostic biomarker here not aiming to deny the importance value of AFP or other makers in clinical practice, but to provide a new alternative choice for physicians to comprehensively assess patients’ survival and help to determine who can benefit most from treatments.